USPTO Patent Examination Standards and Procedures

The United States Patent and Trademark Office (USPTO) applies a structured examination framework to every patent application filed under Title 35 of the U.S. Code. These standards govern how examiners assess patentability, how applicants respond to rejections, and what criteria ultimately determine whether an invention receives a grant of exclusive rights. Understanding examination standards is essential for patent practitioners navigating the patent prosecution process and for applicants seeking predictable outcomes from the USPTO.

Definition and scope

USPTO patent examination is the administrative process by which a trained patent examiner evaluates a pending application against statutory requirements codified in Title 35 of the U.S. Code. The examination determines whether the claimed invention satisfies four core patentability conditions: eligibility under 35 U.S.C. § 101, novelty under 35 U.S.C. § 102, non-obviousness under 35 U.S.C. § 103, and adequate written description, enablement, and definiteness under 35 U.S.C. § 112.

The USPTO's examination authority derives from 35 U.S.C. § 131, which directs the Office to examine applications and issue patents when the applicant is entitled to one. Examination standards are published in the Manual of Patent Examining Procedure (MPEP), a public-facing document that patent examiners and practitioners treat as the primary procedural reference. The MPEP is updated periodically by the USPTO and incorporates guidance from Federal Circuit decisions, Supreme Court rulings, and internal policy memoranda.

The scope of examination covers both procedural compliance and substantive patentability. Procedural review addresses whether the application meets the formal requirements of 37 C.F.R. § 1.51, including specification, claims, drawings, and filing fees. Substantive review applies the statutory patentability framework to every independent and dependent claim.

How it works

Examination follows a defined sequence governed by USPTO rules and MPEP protocols. The process begins when a non-provisional application receives a filing date and is assigned to an art unit — a specialized group of examiners organized by technology classification under the Cooperative Patent Classification (CPC) system, which the USPTO jointly developed with the European Patent Office.

The standard examination sequence proceeds through these phases:

1. Pre-examination processing — The application is checked for formalities, assigned a serial number, and routed to the appropriate art unit based on CPC classification.
2. Prior art search — The examiner searches domestic and foreign patent databases, as well as non-patent literature, to identify references relevant to the claimed invention. The USPTO's search tools include the Patent Full-Text Database and access to databases through the Patent Cooperation Treaty's PatentScope system.
3. First Office Action — The examiner issues a written analysis of the claims, citing any statutory rejections with supporting prior art references. Under 37 C.F.R. § 1.104, the examiner must provide a full statement of reasons for rejection.
4. Applicant response — The applicant has a statutory period, generally 3 months extendable to 6 months under 37 C.F.R. § 1.136, to file arguments, amendments, or both. Response strategy at this stage is covered in depth at /office-action-response.
5. Final Office Action or allowance — Following the response, the examiner either issues a final rejection, allows the application, or issues a new non-final Office Action if new issues arise.
6. Post-final practice — After a final rejection, applicants may file a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114, appeal to the Patent Trial and Appeal Board (PTAB) under 35 U.S.C. § 134, or pursue continuation applications.

The average pendency from filing to first Office Action for utility applications was approximately 16.1 months in fiscal year 2023, according to USPTO performance data.

Common scenarios

Obviousness rejections under § 103 represent the most frequently issued rejection type. The examiner combines two or more prior art references and argues that a person of ordinary skill in the relevant art would have been motivated to combine them to arrive at the claimed invention. The legal standard derives from KSR International Co. v. Teleflex Inc., 550 U.S. 398 (2007), which the Supreme Court decided in 2007 and which the MPEP incorporates at Chapter 2143.

§ 101 eligibility rejections are particularly prominent for software and biotechnology applications. Following the Supreme Court's 2014 decision in Alice Corp. v. CLS Bank International, 573 U.S. 208, examiners apply a two-step framework — the Alice/Mayo test — to determine whether a claim is directed to a patent-ineligible concept and whether it contains an inventive concept sufficient to transform it. The USPTO issued revised 2019 Revised Patent Subject Matter Eligibility Guidance to standardize examiner application of this test.

Anticipation rejections under § 102 assert that a single prior art reference discloses every element of a claimed invention. Under the first-inventor-to-file system established by the America Invents Act (AIA, Pub. L. 112-29, enacted 2011), the effective filing date determines which prior art applies, replacing the prior first-to-invent standard for applications with priority dates on or after March 16, 2013.

§ 112 written description and enablement rejections arise when the specification fails to adequately support the full scope of the claims or fails to teach a person of ordinary skill how to make and use the invention without undue experimentation. These rejections are especially common in broad genus claims in the pharmaceutical and biotechnology sectors.

Decision boundaries

The critical decision points in examination determine whether prosecution proceeds toward allowance, enters an appeal posture, or requires strategic restructuring of the claims.

Examiner vs. applicant burden allocation — Under MPEP § 2142, the examiner bears the initial burden of establishing a prima facie case of unpatentability. Once that burden is met, the burden shifts to the applicant to rebut with evidence or argument. Declaration evidence under 37 C.F.R. § 1.132, such as expert affidavits or objective indicia of non-obviousness (commercial success, long-felt need, failure of others), can overcome a prima facie obviousness rejection.

Final vs. non-final rejections — A non-final rejection permits amendment as a matter of right. A final rejection limits the applicant's options: amendments that place the application in better condition for appeal are entered as a matter of right, but other amendments are entered at the examiner's discretion under 37 C.F.R. § 1.116. This distinction materially affects prosecution strategy.

Appeal thresholds — Appeals from examiner rejections go to the Patent Trial and Appeal Board (PTAB) under 35 U.S.C. § 134(a). PTAB decisions are reviewable by the U.S. Court of Appeals for the Federal Circuit under 35 U.S.C. § 141, or by the U.S. District Court for the Eastern District of Virginia under 35 U.S.C. § 145. The choice between these appellate routes carries different evidentiary and procedural consequences.

Claim scope calibration — Examiners apply the broadest reasonable interpretation (BRI) standard during examination, as established by MPEP § 2111. This standard is broader than the claim construction applied by district courts under Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005). Applicants drafting claims must account for BRI during prosecution while preserving adequate scope for enforcement, a tension explored further in the regulatory context for patent law governing the overall statutory framework.

The full range of examination standards intersects with every aspect of patent strategy. The patentlawauthority.com reference index provides access to related procedural and substantive topics across the patent law framework.